With the new $94 million (€90 million) funding, the company will develop its pipeline of oral macrocycle drugs, nCycles, against validated biologic targets.
Balancing safety and convenience, innovative stick pack designs offer a patient-centric solution for on-the-go dosage forms.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback